In addition to aiding the diagnosis, the role of imaging for patients with known or suspected cardiac sarcoidosis includes estimating the risk of future adverse events (prognosis) as well as identifying individuals who are more likely to benefit from immunosuppressive therapies. When considering these goals, cardiac MRI and PET both visualize different attributes of cardiac sarcoidosis and often have a complementary role. While the absence of late gadolinium enhancement on cardiac MRI has a high negative predictive value for excluding cardiac involvement and identifying patients with an excellent prognosis, PET is better suited for detecting and quantifying the amount of active myocardial inflammation. Data comparing these techniques is limited; however, we recommend that unless contraindications exist, cardiac MRI should be the preferred imaging test for screening patients who have abnormalities that are concerning for cardiac sarcoidosis. However, once disease is identified, PET should be used to determine the response to therapy as well as the burden of active extra-cardiac disease. Notably, cardiac MRI and PET are more sensitive than echocardiography and clinical criteria, and there is often no reliable reference standard to establish the diagnosis of cardiac sarcoidosis. In cases where the diagnosis cannot be clearly established (i.e. clinical and imaging findings which support cardiac sarcoidosis despite the absence of a biopsy), these imaging tests remain useful for informing prognosis as well as guiding therapies.